David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post on X:
“At NOSCM, Julia Rotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP).
I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled.”
More posts featuring Julia Rotow.